Name: rs4244285
Published: September 3, 2024
License: Open Access

Welcome to the Reference SNP (rs) Report

All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs4244285

Current Build 157

Released September 3, 2024

Organism: Homo sapiens
Position: chr10:94781859 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
Alleles: G>A / G>C / G>T
Variation Type: SNV Single Nucleotide Variation
Frequency: A=0.1591252 (200360/1259134, GnomAD_exomes)
A=0.149659 (41331/276168, ALFA)
A=0.160248 (42416/264690, TOPMED) (+ 27 more)
A=0.168061 (24953/148476, GnomAD_genomes)
A=0.185627 (22168/119422, ExAC)
A=0.17413 (13704/78700, PAGE_STUDY)
A=0.29969 (23178/77340, 38KJPN)
A=0.15413 (2004/13002, GO-ESP)
A=0.2767 (1997/7216, Korea4K)
A=0.2155 (1380/6404, 1000G_30X)
A=0.2214 (1109/5008, 1000G)
A=0.1371 (614/4480, Estonian)
A=0.1508 (581/3854, ALSPAC)
A=0.1518 (563/3708, TWINSUK)
A=0.1061 (348/3280, PRJNA289433)
A=0.2765 (810/2930, KOREAN)
A=0.2860 (524/1832, Korea1K)
A=0.142 (142/998, GoNL)
A=0.287 (226/788, PRJEB37584)
A=0.300 (183/611, Vietnamese)
A=0.147 (88/600, NorthernSweden)
A=0.182 (97/534, MGP)
A=0.180 (74/410, PharmGKB)
A=0.186 (60/322, HapMap)
A=0.184 (56/304, FINRISK)
A=0.093 (20/216, Qatari)
G=0.397 (69/174, SGDP_PRJ)
A=0.20 (8/40, GENOME_DK)
G=0.50 (7/14, Siberian)
A=0.50 (7/14, Siberian)

Clinical Significance: Reported in ClinVar
Gene : Consequence: CYP2C19 : Synonymous Variant
Publications: 284 citations
Genomic View: See rs on genome

ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.

Release Version: 20231103111315

Population	Group	Sample Size	Ref Allele	Alt Allele	Ref HMOZ	Alt HMOZ	HTRZ	HWEP
Total	Global	276168	G=0.850341	A=0.149659, T=0.000000	0.724559	0.023877	0.251564	11
European	Sub	237092	G=0.852977	A=0.147023, T=0.000000	0.72846	0.022506	0.249034	4
African	Sub	11456	G=0.82900	A=0.17100, T=0.00000	0.690992	0.032996	0.276013	3
African Others	Sub	434	G=0.820	A=0.180, T=0.000	0.668203	0.02765	0.304147	0
African American	Sub	11022	G=0.82934	A=0.17066, T=0.00000	0.691889	0.033206	0.274905	3
Asian	Sub	3762	G=0.7081	A=0.2919, T=0.0000	0.504519	0.088251	0.40723	0
East Asian	Sub	3020	G=0.7199	A=0.2801, T=0.0000	0.523179	0.083444	0.393377	1
Other Asian	Sub	742	G=0.660	A=0.340, T=0.000	0.428571	0.107817	0.463612	0
Latin American 1	Sub	1380	G=0.8384	A=0.1616, T=0.0000	0.698551	0.021739	0.27971	0
Latin American 2	Sub	6608	G=0.8913	A=0.1087, T=0.0000	0.793281	0.010593	0.196126	0
South Asian	Sub	360	G=0.633	A=0.367, T=0.000	0.405556	0.138889	0.455556	0
Other	Sub	15510	G=0.84894	A=0.15106, T=0.00000	0.723533	0.025661	0.250806	2

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download

Study	Population	Group	Sample Size	Ref Allele	Alt Allele
gnomAD v4 - Exomes	Global	Study-wide	1259134	G=0.8408748	A=0.1591252
gnomAD v4 - Exomes	European	Sub	1094414	G=0.8526344	A=0.1473656
gnomAD v4 - Exomes	South Asian	Sub	60616	G=0.68063	A=0.31937
gnomAD v4 - Exomes	East Asian	Sub	31626	G=0.69775	A=0.30225
gnomAD v4 - Exomes	African	Sub	25872	G=0.81953	A=0.18047
gnomAD v4 - Exomes	Ashkenazi Jewish	Sub	21636	G=0.86754	A=0.13246
gnomAD v4 - Exomes	American	Sub	19654	G=0.89610	A=0.10390
gnomAD v4 - Exomes	Middle Eastern	sub	5316	G=0.8898	A=0.1102
Allele Frequency Aggregator	Total	Global	276168	G=0.850341	A=0.149659, T=0.000000
Allele Frequency Aggregator	European	Sub	237092	G=0.852977	A=0.147023, T=0.000000
Allele Frequency Aggregator	Other	Sub	15510	G=0.84894	A=0.15106, T=0.00000
Allele Frequency Aggregator	African	Sub	11456	G=0.82900	A=0.17100, T=0.00000
Allele Frequency Aggregator	Latin American 2	Sub	6608	G=0.8913	A=0.1087, T=0.0000
Allele Frequency Aggregator	Asian	Sub	3762	G=0.7081	A=0.2919, T=0.0000
Allele Frequency Aggregator	Latin American 1	Sub	1380	G=0.8384	A=0.1616, T=0.0000
Allele Frequency Aggregator	South Asian	Sub	360	G=0.633	A=0.367, T=0.000
TopMed	Global	Study-wide	264690	G=0.839752	A=0.160248
gnomAD v4 - Genomes	Global	Study-wide	148476	G=0.831939	A=0.168061
gnomAD v4 - Genomes	European	Sub	78244	G=0.84694	A=0.15306
gnomAD v4 - Genomes	African	Sub	41316	G=0.82288	A=0.17712
gnomAD v4 - Genomes	American	Sub	15226	G=0.86989	A=0.13011
gnomAD v4 - Genomes	East Asian	Sub	5156	G=0.6881	A=0.3119
gnomAD v4 - Genomes	South Asian	Sub	4780	G=0.6678	A=0.3322
gnomAD v4 - Genomes	Ashkenazi Jewish	Sub	3462	G=0.8680	A=0.1320
gnomAD v4 - Genomes	Middle Eastern	sub	292	G=0.914	A=0.086
ExAC	Global	Study-wide	119422	G=0.814373	A=0.185627
ExAC	Europe	Sub	72574	G=0.84909	A=0.15091
ExAC	Asian	Sub	24618	G=0.67044	A=0.32956
ExAC	American	Sub	11340	G=0.89921	A=0.10079
ExAC	African	Sub	9990	G=0.8190	A=0.1810
ExAC	Other	Sub	900	G=0.831	A=0.169
The PAGE Study	Global	Study-wide	78700	G=0.82587	A=0.17413
The PAGE Study	AfricanAmerican	Sub	32516	G=0.82283	A=0.17717
The PAGE Study	Mexican	Sub	10808	G=0.88166	A=0.11834
The PAGE Study	Asian	Sub	8318	G=0.6970	A=0.3030
The PAGE Study	PuertoRican	Sub	7918	G=0.8603	A=0.1397
The PAGE Study	NativeHawaiian	Sub	4534	G=0.7949	A=0.2051
The PAGE Study	Cuban	Sub	4230	G=0.8619	A=0.1381
The PAGE Study	Dominican	Sub	3828	G=0.8433	A=0.1567
The PAGE Study	CentralAmerican	Sub	2450	G=0.9090	A=0.0910
The PAGE Study	SouthAmerican	Sub	1982	G=0.8875	A=0.1125
The PAGE Study	NativeAmerican	Sub	1260	G=0.8587	A=0.1413
The PAGE Study	SouthAsian	Sub	856	G=0.650	A=0.350
38KJPN	JAPANESE	Study-wide	77340	G=0.70031	A=0.29969
GO Exome Sequencing Project	Global	Study-wide	13002	G=0.84587	A=0.15413
GO Exome Sequencing Project	European American	Sub	8598	G=0.8516	A=0.1484
GO Exome Sequencing Project	African American	Sub	4404	G=0.8347	A=0.1653
Korean Genome Project 4K	KOREAN	Study-wide	7216	G=0.7233	A=0.2767
1000Genomes_30X	Global	Study-wide	6404	G=0.7845	A=0.2155
1000Genomes_30X	African	Sub	1786	G=0.8387	A=0.1613
1000Genomes_30X	Europe	Sub	1266	G=0.8578	A=0.1422
1000Genomes_30X	South Asian	Sub	1202	G=0.6448	A=0.3552
1000Genomes_30X	East Asian	Sub	1170	G=0.6778	A=0.3222
1000Genomes_30X	American	Sub	980	G=0.890	A=0.110
1000Genomes	Global	Study-wide	5008	G=0.7786	A=0.2214
1000Genomes	African	Sub	1322	G=0.8298	A=0.1702
1000Genomes	East Asian	Sub	1008	G=0.6875	A=0.3125
1000Genomes	Europe	Sub	1006	G=0.8549	A=0.1451
1000Genomes	South Asian	Sub	978	G=0.642	A=0.358
1000Genomes	American	Sub	694	G=0.895	A=0.105
Genetic variation in the Estonian population	Estonian	Study-wide	4480	G=0.8629	A=0.1371
The Avon Longitudinal Study of Parents and Children	PARENT AND CHILD COHORT	Study-wide	3854	G=0.8492	A=0.1508
UK 10K study - Twins	TWIN COHORT	Study-wide	3708	G=0.8482	A=0.1518
MxGDAR/Encodat-PGx	Global	Study-wide	3280	G=0.8939	A=0.1061
MxGDAR/Encodat-PGx	MxGDAR	Sub	3280	G=0.8939	A=0.1061
KOREAN population from KRGDB	KOREAN	Study-wide	2930	G=0.7235	A=0.2765
Korean Genome Project	KOREAN	Study-wide	1832	G=0.7140	A=0.2860
Genome of the Netherlands Release 5	Genome of the Netherlands	Study-wide	998	G=0.858	A=0.142
CNV burdens in cranial meningiomas	Global	Study-wide	788	G=0.713	A=0.287
CNV burdens in cranial meningiomas	CRM	Sub	788	G=0.713	A=0.287
A Vietnamese Genetic Variation Database	Global	Study-wide	611	G=0.700	A=0.300
Northern Sweden	ACPOP	Study-wide	600	G=0.853	A=0.147
Medical Genome Project healthy controls from Spanish population	Spanish controls	Study-wide	534	G=0.818	A=0.182
PharmGKB Aggregated	Global	Study-wide	410	G=0.820	A=0.180
PharmGKB Aggregated	PA150051974	Sub	352	G=0.807	A=0.193
PharmGKB Aggregated	PA130150462	Sub	58	G=0.90	A=0.10
HapMap	Global	Study-wide	322	G=0.814	A=0.186
HapMap	African	Sub	118	G=0.856	A=0.144
HapMap	American	Sub	116	G=0.845	A=0.155
HapMap	Asian	Sub	88	G=0.72	A=0.28
FINRISK	Finnish from FINRISK project	Study-wide	304	G=0.816	A=0.184
Qatari	Global	Study-wide	216	G=0.907	A=0.093
SGDP_PRJ	Global	Study-wide	174	G=0.397	A=0.603
The Danish reference pan genome	Danish	Study-wide	40	G=0.80	A=0.20
Siberian	Global	Study-wide	14	G=0.50	A=0.50

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements

Sequence name	Change
GRCh38.p14 chr 10	NC_000010.11:g.94781859G>A
GRCh38.p14 chr 10	NC_000010.11:g.94781859G>C
GRCh38.p14 chr 10	NC_000010.11:g.94781859G>T
GRCh37.p13 chr 10	NC_000010.10:g.96541616G>A
GRCh37.p13 chr 10	NC_000010.10:g.96541616G>C
GRCh37.p13 chr 10	NC_000010.10:g.96541616G>T
CYP2C19 RefSeqGene (LRG_584)	NG_008384.3:g.24179G>A
CYP2C19 RefSeqGene (LRG_584)	NG_008384.3:g.24179G>C
CYP2C19 RefSeqGene (LRG_584)	NG_008384.3:g.24179G>T

Gene: CYP2C19, cytochrome P450 family 2 subfamily C member 19 (plus strand)

Molecule type	Change	Amino acid[Codon]	SO Term
CYP2C19 transcript	NM_000769.4:c.681G>A	P [CCG] > P [CCA]	Coding Sequence Variant
cytochrome P450 2C19	NP_000760.1:p.Pro227=	P (Pro) > P (Pro)	Synonymous Variant
CYP2C19 transcript	NM_000769.4:c.681G>C	P [CCG] > P [CCC]	Coding Sequence Variant
cytochrome P450 2C19	NP_000760.1:p.Pro227=	P (Pro) > P (Pro)	Synonymous Variant
CYP2C19 transcript	NM_000769.4:c.681G>T	P [CCG] > P [CCT]	Coding Sequence Variant
cytochrome P450 2C19	NP_000760.1:p.Pro227=	P (Pro) > P (Pro)	Synonymous Variant

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: A (allele ID: 31936 )

ClinVar Accession	Disease Names	Clinical Significance
RCV000018393.33	Mephenytoin, poor metabolism of	Drug-Response
RCV000018394.37	Proguanil, poor metabolism of	Drug-Response
RCV000018395.35	Clopidogrel response	Drug-Response
RCV000352637.13	not provided	Other
RCV000610614.9	not specified	Likely-Benign
RCV000782440.10	Clopidogrel response	Drug-Response
RCV000782448.11	Clopidogrel response	Drug-Response
RCV000782449.10	Clopidogrel response	Drug-Response
RCV000782450.9	Clopidogrel response	Drug-Response
RCV000782451.10	Clopidogrel response	Drug-Response
RCV000782452.10	Clopidogrel response	Drug-Response
RCV000782453.10	Clopidogrel response	Drug-Response
RCV000782488.10	Citalopram response	Drug-Response
RCV000782513.10	Escitalopram response	Drug-Response
RCV000782514.11	Citalopram response	Drug-Response
RCV000782515.11	Escitalopram response	Drug-Response
RCV000782516.10	Citalopram response	Drug-Response
RCV000782517.10	Escitalopram response	Drug-Response
RCV000782518.10	Citalopram response	Drug-Response
RCV000782519.10	Escitalopram response	Drug-Response
RCV000782634.10	Escitalopram response	Drug-Response
RCV000782635.10	Citalopram response	Drug-Response
RCV000782636.10	Escitalopram response	Drug-Response
RCV000782637.10	Citalopram response	Drug-Response
RCV000782638.10	Escitalopram response	Drug-Response
RCV000782639.10	Citalopram response	Drug-Response
RCV000782640.10	Escitalopram response	Drug-Response
RCV000782690.10	Escitalopram response	Drug-Response
RCV000782691.10	Citalopram response	Drug-Response
RCV000782692.10	Escitalopram response	Drug-Response
RCV000782693.10	Citalopram response	Drug-Response
RCV000782694.10	Escitalopram response	Drug-Response
RCV000782695.10	Citalopram response	Drug-Response
RCV000782696.10	Escitalopram response	Drug-Response
RCV000782697.9	Citalopram response	Drug-Response
RCV000782698.10	Escitalopram response	Drug-Response
RCV000782699.10	Citalopram response	Drug-Response
RCV000782700.10	Escitalopram response	Drug-Response
RCV000782880.10	Citalopram response	Drug-Response
RCV000782881.10	Escitalopram response	Drug-Response
RCV000782882.10	Citalopram response	Drug-Response
RCV000782883.10	Escitalopram response	Drug-Response
RCV000782884.10	Citalopram response	Drug-Response
RCV000782885.10	Escitalopram response	Drug-Response
RCV000782886.10	Citalopram response	Drug-Response
RCV000782887.10	Escitalopram response	Drug-Response
RCV000783140.10	Sertraline response	Drug-Response
RCV000783141.10	Sertraline response	Drug-Response
RCV000783142.10	Sertraline response	Drug-Response
RCV000783143.10	Sertraline response	Drug-Response
RCV000783144.10	Sertraline response	Drug-Response
RCV000783145.10	Sertraline response	Drug-Response
RCV000783171.10	Sertraline response	Drug-Response
RCV000783172.10	Sertraline response	Drug-Response
RCV000783173.10	Sertraline response	Drug-Response
RCV000783174.10	Sertraline response	Drug-Response
RCV000783175.10	Sertraline response	Drug-Response
RCV000783269.10	Sertraline response	Drug-Response
RCV000783270.10	Sertraline response	Drug-Response
RCV000783415.10	Voriconazole response	Drug-Response
RCV000783416.10	Voriconazole response	Drug-Response
RCV000783417.10	Voriconazole response	Drug-Response
RCV000783418.10	Voriconazole response	Drug-Response
RCV000783500.10	Voriconazole response	Drug-Response
RCV000783514.10	Voriconazole response	Drug-Response
RCV000783515.10	Voriconazole response	Drug-Response
RCV000783575.10	Voriconazole response	Drug-Response
RCV000783576.10	Voriconazole response	Drug-Response
RCV000783577.10	Voriconazole response	Drug-Response
RCV000783578.10	Voriconazole response	Drug-Response
RCV000783613.10	Voriconazole response	Drug-Response
RCV000783614.10	Voriconazole response	Drug-Response
RCV000783615.10	Voriconazole response	Drug-Response
RCV000783616.9	Voriconazole response	Drug-Response
RCV000783617.10	Voriconazole response	Drug-Response
RCV000783618.10	Voriconazole response	Drug-Response
RCV000783619.10	Voriconazole response	Drug-Response
RCV000783620.10	Voriconazole response	Drug-Response
RCV000783648.10	CYP2C19: no function	Drug-Response
RCV000783666.11	Clopidogrel response	Drug-Response
RCV000783672.10	Clopidogrel response	Drug-Response
RCV000783673.10	Clopidogrel response	Drug-Response
RCV000783712.10	Escitalopram response	Drug-Response
RCV000783739.10	Citalopram response	Drug-Response
RCV000783740.10	Escitalopram response	Drug-Response
RCV000783741.10	Citalopram response	Drug-Response
RCV000783742.10	Escitalopram response	Drug-Response
RCV000783743.10	Citalopram response	Drug-Response
RCV000783864.10	Citalopram response	Drug-Response
RCV000783865.10	Escitalopram response	Drug-Response
RCV000783866.10	Citalopram response	Drug-Response
RCV000783867.10	Escitalopram response	Drug-Response
RCV000783868.10	Citalopram response	Drug-Response
RCV000783922.11	Citalopram response	Drug-Response
RCV000783923.11	Escitalopram response	Drug-Response
RCV000783924.10	Citalopram response	Drug-Response
RCV000783925.9	Escitalopram response	Drug-Response
RCV000783926.10	Citalopram response	Drug-Response
RCV000783927.10	Escitalopram response	Drug-Response
RCV000783928.10	Citalopram response	Drug-Response
RCV000783929.10	Escitalopram response	Drug-Response
RCV000783930.10	Citalopram response	Drug-Response
RCV000783931.10	Escitalopram response	Drug-Response
RCV000783932.10	Citalopram response	Drug-Response
RCV000784107.10	Citalopram response	Drug-Response
RCV000784108.10	Escitalopram response	Drug-Response
RCV000784109.10	Citalopram response	Drug-Response
RCV000784110.10	Escitalopram response	Drug-Response
RCV000784111.10	Citalopram response	Drug-Response
RCV000784112.10	Escitalopram response	Drug-Response
RCV000784113.10	Citalopram response	Drug-Response
RCV000784114.10	Escitalopram response	Drug-Response
RCV000784115.10	Citalopram response	Drug-Response
RCV000784116.10	Escitalopram response	Drug-Response
RCV000784117.10	Citalopram response	Drug-Response
RCV000784118.10	Escitalopram response	Drug-Response
RCV000784302.10	Sertraline response	Drug-Response
RCV000784312.10	Sertraline response	Drug-Response
RCV000784313.10	Sertraline response	Drug-Response
RCV000784314.10	Sertraline response	Drug-Response
RCV000784315.11	Sertraline response	Drug-Response
RCV000784316.10	Sertraline response	Drug-Response
RCV000784317.10	Sertraline response	Drug-Response
RCV000784403.11	Sertraline response	Drug-Response
RCV000784404.10	Sertraline response	Drug-Response
RCV000784405.10	Sertraline response	Drug-Response
RCV000784406.10	Sertraline response	Drug-Response
RCV000784407.10	Sertraline response	Drug-Response
RCV000784408.9	Sertraline response	Drug-Response
RCV000784498.10	Sertraline response	Drug-Response
RCV000784499.10	Sertraline response	Drug-Response
RCV000784500.10	Sertraline response	Drug-Response
RCV000784501.10	Sertraline response	Drug-Response
RCV000784502.10	Sertraline response	Drug-Response
RCV000784503.10	Sertraline response	Drug-Response
RCV000784504.10	Sertraline response	Drug-Response
RCV000784505.10	Sertraline response	Drug-Response
RCV000784648.10	Voriconazole response	Drug-Response
RCV000784649.10	Voriconazole response	Drug-Response
RCV000784650.10	Voriconazole response	Drug-Response
RCV000784651.10	Voriconazole response	Drug-Response
RCV000784652.10	Voriconazole response	Drug-Response
RCV000784653.10	Voriconazole response	Drug-Response
RCV000784749.10	Voriconazole response	Drug-Response
RCV000784750.10	Voriconazole response	Drug-Response
RCV000784751.10	Voriconazole response	Drug-Response
RCV000784752.11	Voriconazole response	Drug-Response
RCV000784797.10	Voriconazole response	Drug-Response
RCV000784798.10	Voriconazole response	Drug-Response
RCV000784838.11	Voriconazole response	Drug-Response
RCV000784839.10	Voriconazole response	Drug-Response
RCV000784840.10	Voriconazole response	Drug-Response

Allele: T (allele ID: 1695652 )

ClinVar Accession	Disease Names	Clinical Significance
RCV002280383.1	Acute coronary syndrome	Drug-Response

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement	G=	A	C	T
GRCh38.p14 chr 10	NC_000010.11:g.94781859=	NC_000010.11:g.94781859G>A	NC_000010.11:g.94781859G>C	NC_000010.11:g.94781859G>T
GRCh37.p13 chr 10	NC_000010.10:g.96541616=	NC_000010.10:g.96541616G>A	NC_000010.10:g.96541616G>C	NC_000010.10:g.96541616G>T
CYP2C19 RefSeqGene (LRG_584)	NG_008384.3:g.24179=	NG_008384.3:g.24179G>A	NG_008384.3:g.24179G>C	NG_008384.3:g.24179G>T
CYP2C19 transcript	NM_000769.4:c.681=	NM_000769.4:c.681G>A	NM_000769.4:c.681G>C	NM_000769.4:c.681G>T
CYP2C19 transcript	NM_000769.3:c.681=	NM_000769.3:c.681G>A	NM_000769.3:c.681G>C	NM_000769.3:c.681G>T
CYP2C19 transcript	NM_000769.2:c.681=	NM_000769.2:c.681G>A	NM_000769.2:c.681G>C	NM_000769.2:c.681G>T
CYP2C19 transcript	NM_000769.1:c.681=	NM_000769.1:c.681G>A	NM_000769.1:c.681G>C	NM_000769.1:c.681G>T
cytochrome P450 2C19	NP_000760.1:p.Pro227=	NP_000760.1:p.Pro227=	NP_000760.1:p.Pro227=	NP_000760.1:p.Pro227=

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

160 SubSNP, 29 Frequency, 153 ClinVar submissions

No	Submitter	Submission ID	Date (Build)
1	SC_JCM	ss6273387	Sep 28, 2016 (149)
2	SSAHASNP	ss20712232	Apr 05, 2004 (121)
3	PERLEGEN	ss24092249	Sep 20, 2004 (123)
4	EGP_SNPS	ss28531447	Dec 02, 2004 (126)
5	BIOVENTURES	ss32475261	May 24, 2005 (125)
6	ABI	ss38568858	Mar 11, 2006 (126)
7	ILLUMINA	ss65746807	Oct 16, 2006 (127)
8	EGP_SNPS	ss66862485	Dec 01, 2006 (127)
9	PHARMGKB_COBRA	ss69370430	May 17, 2007 (127)
10	SI_EXO	ss71644820	May 17, 2007 (127)
11	CGM_KYOTO	ss76860176	Dec 07, 2007 (129)
12	CCHMC-CAE-PGCORE	ss79314148	Dec 15, 2007 (130)
13	PHARMGKB_AB_DME	ss84155548	Dec 15, 2007 (130)
14	HUMANGENOME_JCVI	ss97576553	Feb 06, 2009 (130)
15	1000GENOMES	ss109668150	Jan 24, 2009 (130)
16	ENSEMBL	ss137888266	Dec 01, 2009 (131)
17	SEATTLESEQ	ss159721122	Dec 01, 2009 (131)
18	ILLUMINA	ss160667511	Dec 01, 2009 (131)
19	1000GENOMES	ss224884225	Jul 14, 2010 (132)
20	1000GENOMES	ss235292670	Jul 15, 2010 (132)
21	1000GENOMES	ss241975895	Jul 15, 2010 (132)
22	ILLUMINA	ss244267390	Jul 04, 2010 (132)
23	BL	ss254534604	May 09, 2011 (134)
24	GMI	ss280732378	May 04, 2012 (137)
25	PJP	ss290909232	May 09, 2011 (134)
26	NHLBI-ESP	ss342304122	May 09, 2011 (134)
27	ILLUMINA	ss480908553	May 04, 2012 (137)
28	ILLUMINA	ss480927569	May 04, 2012 (137)
29	ILLUMINA	ss481884803	Sep 08, 2015 (146)
30	ILLUMINA	ss485249287	May 04, 2012 (137)
31	1000GENOMES	ss491001642	May 04, 2012 (137)
32	CLINSEQ_SNP	ss491629939	May 04, 2012 (137)
33	ILLUMINA	ss537221024	Sep 08, 2015 (146)
34	SSMP	ss657184049	Apr 25, 2013 (138)
35	ILLUMINA	ss778532112	Sep 08, 2015 (146)
36	ILLUMINA	ss783070592	Sep 08, 2015 (146)
37	ILLUMINA	ss784028424	Sep 08, 2015 (146)
38	ILLUMINA	ss832328705	Sep 08, 2015 (146)
39	ILLUMINA	ss833988650	Sep 08, 2015 (146)
40	JMKIDD_LAB	ss974475596	Aug 21, 2014 (142)
41	EVA-GONL	ss987804539	Aug 21, 2014 (142)
42	JMKIDD_LAB	ss1067514945	Aug 21, 2014 (142)
43	JMKIDD_LAB	ss1077215449	Aug 21, 2014 (142)
44	1000GENOMES	ss1338623797	Aug 21, 2014 (142)
45	OMIM-CURATED-RECORDS	ss1505810974	Oct 12, 2018 (152)
46	EVA_GENOME_DK	ss1575296741	Apr 01, 2015 (144)
47	EVA_FINRISK	ss1584069479	Apr 01, 2015 (144)
48	EVA_DECODE	ss1597477850	Apr 01, 2015 (144)
49	EVA_UK10K_ALSPAC	ss1625196200	Apr 01, 2015 (144)
50	EVA_UK10K_TWINSUK	ss1668190233	Apr 01, 2015 (144)
51	EVA_EXAC	ss1690011937	Apr 01, 2015 (144)
52	EVA_MGP	ss1711265773	Apr 01, 2015 (144)
53	ILLUMINA	ss1751988282	Sep 08, 2015 (146)
54	WEILL_CORNELL_DGM	ss1931170553	Feb 12, 2016 (147)
55	ILLUMINA	ss1946289782	Feb 12, 2016 (147)
56	ILLUMINA	ss1959284952	Feb 12, 2016 (147)
57	GENOMED	ss1967199824	Jul 19, 2016 (147)
58	JJLAB	ss2026313671	Sep 14, 2016 (149)
59	USC_VALOUEV	ss2154590332	Nov 08, 2017 (151)
60	HUMAN_LONGEVITY	ss2177148642	Dec 20, 2016 (150)
61	SYSTEMSBIOZJU	ss2627625777	Nov 08, 2017 (151)
62	ILLUMINA	ss2632748384	Nov 08, 2017 (151)
63	GRF	ss2698843075	Nov 08, 2017 (151)
64	ILLUMINA	ss2710661490	Nov 08, 2017 (151)
65	GNOMAD	ss2738420845	Nov 08, 2017 (151)
66	GNOMAD	ss2748441509	Nov 08, 2017 (151)
67	GNOMAD	ss2892128580	Nov 08, 2017 (151)
68	SWEGEN	ss3006966091	Nov 08, 2017 (151)
69	BIOINF_KMB_FNS_UNIBA	ss3026946939	Nov 08, 2017 (151)
70	CSIRBIOHTS	ss3029638026	Nov 08, 2017 (151)
71	CSHL	ss3349261285	Nov 08, 2017 (151)
72	ILLUMINA	ss3625584961	Oct 12, 2018 (152)
73	ILLUMINA	ss3626509917	Oct 12, 2018 (152)
74	ILLUMINA	ss3630771631	Oct 12, 2018 (152)
75	ILLUMINA	ss3632960313	Oct 12, 2018 (152)
76	ILLUMINA	ss3633657957	Oct 12, 2018 (152)
77	ILLUMINA	ss3634417821	Oct 12, 2018 (152)
78	ILLUMINA	ss3635350236	Oct 12, 2018 (152)
79	ILLUMINA	ss3636102025	Oct 12, 2018 (152)
80	ILLUMINA	ss3637100941	Oct 12, 2018 (152)
81	ILLUMINA	ss3640125162	Oct 12, 2018 (152)
82	ILLUMINA	ss3644542529	Oct 12, 2018 (152)
83	OMUKHERJEE_ADBS	ss3646413622	Oct 12, 2018 (152)
84	URBANLAB	ss3649441579	Oct 12, 2018 (152)
85	EGCUT_WGS	ss3674378253	Jul 13, 2019 (153)
86	EVA_DECODE	ss3690461995	Jul 13, 2019 (153)
87	ACPOP	ss3737585613	Jul 13, 2019 (153)
88	ILLUMINA	ss3744074659	Jul 13, 2019 (153)
89	ILLUMINA	ss3744718792	Jul 13, 2019 (153)
90	EVA	ss3748468432	Jul 13, 2019 (153)
91	PAGE_CC	ss3771575725	Jul 13, 2019 (153)
92	ILLUMINA	ss3772219148	Jul 13, 2019 (153)
93	KHV_HUMAN_GENOMES	ss3813834603	Jul 13, 2019 (153)
94	EVA	ss3824540950	Apr 26, 2020 (154)
95	EVA	ss3825780773	Apr 26, 2020 (154)
96	EVA	ss3832276858	Apr 26, 2020 (154)
97	EVA	ss3839679578	Apr 26, 2020 (154)
98	EVA	ss3845153244	Apr 26, 2020 (154)
99	SGDP_PRJ	ss3874827656	Apr 26, 2020 (154)
100	KRGDB	ss3922955812	Apr 26, 2020 (154)
101	KOGIC	ss3968458465	Apr 26, 2020 (154)
102	FSA-LAB	ss3983983378	Apr 26, 2021 (155)
103	EVA	ss3984449114	Apr 26, 2021 (155)
104	EVA	ss3984639037	Apr 26, 2021 (155)
105	EVA	ss3986493465	Apr 26, 2021 (155)
106	TOPMED	ss4862628816	Apr 26, 2021 (155)
107	TOMMO_GENOMICS	ss6114202115	Nov 01, 2024 (157)
108	EVA	ss6253826834	Nov 01, 2024 (157)
109	EVA	ss6307410302	Nov 01, 2024 (157)
110	EVA	ss6322063341	Nov 01, 2024 (157)
111	EVA	ss6322395607	Nov 01, 2024 (157)
112	EVA	ss6326442677	Nov 01, 2024 (157)
113	EVA	ss6332060696	Nov 01, 2024 (157)
114	YEGNASUBRAMANIAN_LAB	ss6343187327	Nov 01, 2024 (157)
115	EVA	ss6349787544	Nov 01, 2024 (157)
116	EVA	ss6349997714	Nov 01, 2024 (157)
117	KOGIC	ss6382289085	Nov 01, 2024 (157)
118	EVA	ss6403982928	Nov 01, 2024 (157)
119	EVA	ss6404050381	Nov 01, 2024 (157)
120	EVA	ss6404454508	Nov 01, 2024 (157)
121	GNOMAD	ss6440423965	Nov 01, 2024 (157)
122	GNOMAD	ss6859879643	Nov 01, 2024 (157)
123	TOMMO_GENOMICS	ss8198969276	Nov 01, 2024 (157)
124	EVA	ss8236886080	Nov 01, 2024 (157)
125	EVA	ss8237481903	Nov 01, 2024 (157)
126	EVA	ss8237481904	Nov 01, 2024 (157)
127	EVA	ss8237481905	Nov 01, 2024 (157)
128	EVA	ss8237481906	Nov 01, 2024 (157)
129	QINSY-LAB	ss8237630501	Nov 01, 2024 (157)
130	EVA	ss8237655806	Nov 01, 2024 (157)
131	1000G_HIGH_COVERAGE	ss8285088098	Nov 01, 2024 (157)
132	TRAN_CS_UWATERLOO	ss8314429328	Nov 01, 2024 (157)
133	EVA	ss8315494519	Nov 01, 2024 (157)
134	HUGCELL_USP	ss8480548060	Nov 01, 2024 (157)
135	EVA	ss8510129403	Nov 01, 2024 (157)
136	EVA	ss8512473898	Nov 01, 2024 (157)
137	1000G_HIGH_COVERAGE	ss8579565104	Nov 01, 2024 (157)
138	EVA	ss8623950097	Nov 01, 2024 (157)
139	EVA	ss8624011473	Nov 01, 2024 (157)
140	SANFORD_IMAGENETICS	ss8624255707	Nov 01, 2024 (157)
141	SANFORD_IMAGENETICS	ss8649886005	Nov 01, 2024 (157)
142	TOMMO_GENOMICS	ss8745187076	Nov 01, 2024 (157)
143	EVA	ss8799403698	Nov 01, 2024 (157)
144	EVA	ss8799821536	Nov 01, 2024 (157)
145	EVA	ss8800062047	Nov 01, 2024 (157)
146	EVA	ss8800161207	Nov 01, 2024 (157)
147	YY_MCH	ss8811792439	Nov 01, 2024 (157)
148	EVA	ss8824807546	Nov 01, 2024 (157)
149	EVA	ss8847378110	Nov 01, 2024 (157)
150	EVA	ss8847605634	Nov 01, 2024 (157)
151	EVA	ss8848304486	Nov 01, 2024 (157)
152	EVA	ss8849697153	Nov 01, 2024 (157)
153	EVA	ss8880086142	Nov 01, 2024 (157)
154	EVA	ss8941172579	Nov 01, 2024 (157)
155	CAD-JSPH	ss8981325922	Nov 01, 2024 (157)
156	EVA	ss8981728093	Nov 01, 2024 (157)
157	EVA	ss8981728094	Nov 01, 2024 (157)
158	EVA	ss8982040320	Nov 01, 2024 (157)
159	MYSEQ1_SNP	ss8982064789	Nov 01, 2024 (157)
160	EVA	ss8982151829	Nov 01, 2024 (157)
161	1000Genomes	NC_000010.10 - 96541616	Oct 12, 2018 (152)
162	1000Genomes_30X	NC_000010.11 - 94781859	Nov 01, 2024 (157)
163	The Avon Longitudinal Study of Parents and Children	NC_000010.10 - 96541616	Oct 12, 2018 (152)
164	Genetic variation in the Estonian population	NC_000010.10 - 96541616	Oct 12, 2018 (152)
165	ExAC	NC_000010.10 - 96541616	Oct 12, 2018 (152)
166	FINRISK	NC_000010.10 - 96541616	Apr 26, 2020 (154)
167	The Danish reference pan genome	NC_000010.10 - 96541616	Apr 26, 2020 (154)
168	gnomAD v4 - Exomes	NC_000010.11 - 94781859	Nov 01, 2024 (157)
169	gnomAD v4 - Genomes	NC_000010.11 - 94781859	Nov 01, 2024 (157)
170	GO Exome Sequencing Project	NC_000010.10 - 96541616	Oct 12, 2018 (152)
171	Genome of the Netherlands Release 5	NC_000010.10 - 96541616	Apr 26, 2020 (154)
172	HapMap	NC_000010.11 - 94781859	Apr 26, 2020 (154)
173	KOREAN population from KRGDB	NC_000010.10 - 96541616	Apr 26, 2020 (154)
174	Korean Genome Project	NC_000010.11 - 94781859	Apr 26, 2020 (154)
175	Korean Genome Project 4K	NC_000010.11 - 94781859	Nov 01, 2024 (157)
176	Medical Genome Project healthy controls from Spanish population	NC_000010.10 - 96541616	Apr 26, 2020 (154)
177	Northern Sweden	NC_000010.10 - 96541616	Jul 13, 2019 (153)
178	The PAGE Study	NC_000010.11 - 94781859	Jul 13, 2019 (153)
179	CNV burdens in cranial meningiomas	NC_000010.10 - 96541616	Apr 26, 2021 (155)
180	MxGDAR/Encodat-PGx	NC_000010.10 - 96541616	Apr 26, 2021 (155)
181	PharmGKB Aggregated	NC_000010.11 - 94781859	Apr 26, 2020 (154)
182	Qatari	NC_000010.10 - 96541616	Apr 26, 2020 (154)
183	SGDP_PRJ	NC_000010.10 - 96541616	Apr 26, 2020 (154)
184	Siberian	NC_000010.10 - 96541616	Apr 26, 2020 (154)
185	38KJPN	NC_000010.11 - 94781859	Nov 01, 2024 (157)
186	TopMed	NC_000010.11 - 94781859	Apr 26, 2021 (155)
187	UK 10K study - Twins	NC_000010.10 - 96541616	Oct 12, 2018 (152)
188	A Vietnamese Genetic Variation Database	NC_000010.10 - 96541616	Jul 13, 2019 (153)
189	ALFA	NC_000010.11 - 94781859	Nov 01, 2024 (157)
190	ClinVar	RCV000018393.33	Nov 01, 2024 (157)
191	ClinVar	RCV000018394.37	Nov 01, 2024 (157)
192	ClinVar	RCV000018395.35	Nov 01, 2024 (157)
193	ClinVar	RCV000352637.13	Nov 01, 2024 (157)
194	ClinVar	RCV000610614.9	Nov 01, 2024 (157)
195	ClinVar	RCV000782440.10	Nov 01, 2024 (157)
196	ClinVar	RCV000782448.11	Nov 01, 2024 (157)
197	ClinVar	RCV000782449.10	Nov 01, 2024 (157)
198	ClinVar	RCV000782450.9	Nov 01, 2024 (157)
199	ClinVar	RCV000782451.10	Nov 01, 2024 (157)
200	ClinVar	RCV000782452.10	Nov 01, 2024 (157)
201	ClinVar	RCV000782453.10	Nov 01, 2024 (157)
202	ClinVar	RCV000782488.10	Nov 01, 2024 (157)
203	ClinVar	RCV000782513.10	Nov 01, 2024 (157)
204	ClinVar	RCV000782514.11	Nov 01, 2024 (157)
205	ClinVar	RCV000782515.11	Nov 01, 2024 (157)
206	ClinVar	RCV000782516.10	Nov 01, 2024 (157)
207	ClinVar	RCV000782517.10	Nov 01, 2024 (157)
208	ClinVar	RCV000782518.10	Nov 01, 2024 (157)
209	ClinVar	RCV000782519.10	Nov 01, 2024 (157)
210	ClinVar	RCV000782634.10	Nov 01, 2024 (157)
211	ClinVar	RCV000782635.10	Nov 01, 2024 (157)
212	ClinVar	RCV000782636.10	Nov 01, 2024 (157)
213	ClinVar	RCV000782637.10	Nov 01, 2024 (157)
214	ClinVar	RCV000782638.10	Nov 01, 2024 (157)
215	ClinVar	RCV000782639.10	Nov 01, 2024 (157)
216	ClinVar	RCV000782640.10	Nov 01, 2024 (157)
217	ClinVar	RCV000782690.10	Nov 01, 2024 (157)
218	ClinVar	RCV000782691.10	Nov 01, 2024 (157)
219	ClinVar	RCV000782692.10	Nov 01, 2024 (157)
220	ClinVar	RCV000782693.10	Nov 01, 2024 (157)
221	ClinVar	RCV000782694.10	Nov 01, 2024 (157)
222	ClinVar	RCV000782695.10	Nov 01, 2024 (157)
223	ClinVar	RCV000782696.10	Nov 01, 2024 (157)
224	ClinVar	RCV000782697.9	Nov 01, 2024 (157)
225	ClinVar	RCV000782698.10	Nov 01, 2024 (157)
226	ClinVar	RCV000782699.10	Nov 01, 2024 (157)
227	ClinVar	RCV000782700.10	Nov 01, 2024 (157)
228	ClinVar	RCV000782880.10	Nov 01, 2024 (157)
229	ClinVar	RCV000782881.10	Nov 01, 2024 (157)
230	ClinVar	RCV000782882.10	Nov 01, 2024 (157)
231	ClinVar	RCV000782883.10	Nov 01, 2024 (157)
232	ClinVar	RCV000782884.10	Nov 01, 2024 (157)
233	ClinVar	RCV000782885.10	Nov 01, 2024 (157)
234	ClinVar	RCV000782886.10	Nov 01, 2024 (157)
235	ClinVar	RCV000782887.10	Nov 01, 2024 (157)
236	ClinVar	RCV000783140.10	Nov 01, 2024 (157)
237	ClinVar	RCV000783141.10	Nov 01, 2024 (157)
238	ClinVar	RCV000783142.10	Nov 01, 2024 (157)
239	ClinVar	RCV000783143.10	Nov 01, 2024 (157)
240	ClinVar	RCV000783144.10	Nov 01, 2024 (157)
241	ClinVar	RCV000783145.10	Nov 01, 2024 (157)
242	ClinVar	RCV000783171.10	Nov 01, 2024 (157)
243	ClinVar	RCV000783172.10	Nov 01, 2024 (157)
244	ClinVar	RCV000783173.10	Nov 01, 2024 (157)
245	ClinVar	RCV000783174.10	Nov 01, 2024 (157)
246	ClinVar	RCV000783175.10	Nov 01, 2024 (157)
247	ClinVar	RCV000783269.10	Nov 01, 2024 (157)
248	ClinVar	RCV000783270.10	Nov 01, 2024 (157)
249	ClinVar	RCV000783415.10	Nov 01, 2024 (157)
250	ClinVar	RCV000783416.10	Nov 01, 2024 (157)
251	ClinVar	RCV000783417.10	Nov 01, 2024 (157)
252	ClinVar	RCV000783418.10	Nov 01, 2024 (157)
253	ClinVar	RCV000783500.10	Nov 01, 2024 (157)
254	ClinVar	RCV000783514.10	Nov 01, 2024 (157)
255	ClinVar	RCV000783515.10	Nov 01, 2024 (157)
256	ClinVar	RCV000783575.10	Nov 01, 2024 (157)
257	ClinVar	RCV000783576.10	Nov 01, 2024 (157)
258	ClinVar	RCV000783577.10	Nov 01, 2024 (157)
259	ClinVar	RCV000783578.10	Nov 01, 2024 (157)
260	ClinVar	RCV000783613.10	Nov 01, 2024 (157)
261	ClinVar	RCV000783614.10	Nov 01, 2024 (157)
262	ClinVar	RCV000783615.10	Nov 01, 2024 (157)
263	ClinVar	RCV000783616.9	Nov 01, 2024 (157)
264	ClinVar	RCV000783617.10	Nov 01, 2024 (157)
265	ClinVar	RCV000783618.10	Nov 01, 2024 (157)
266	ClinVar	RCV000783619.10	Nov 01, 2024 (157)
267	ClinVar	RCV000783620.10	Nov 01, 2024 (157)
268	ClinVar	RCV000783648.10	Nov 01, 2024 (157)
269	ClinVar	RCV000783666.11	Nov 01, 2024 (157)
270	ClinVar	RCV000783672.10	Nov 01, 2024 (157)
271	ClinVar	RCV000783673.10	Nov 01, 2024 (157)
272	ClinVar	RCV000783712.10	Nov 01, 2024 (157)
273	ClinVar	RCV000783739.10	Nov 01, 2024 (157)
274	ClinVar	RCV000783740.10	Nov 01, 2024 (157)
275	ClinVar	RCV000783741.10	Nov 01, 2024 (157)
276	ClinVar	RCV000783742.10	Nov 01, 2024 (157)
277	ClinVar	RCV000783743.10	Nov 01, 2024 (157)
278	ClinVar	RCV000783864.10	Nov 01, 2024 (157)
279	ClinVar	RCV000783865.10	Nov 01, 2024 (157)
280	ClinVar	RCV000783866.10	Nov 01, 2024 (157)
281	ClinVar	RCV000783867.10	Nov 01, 2024 (157)
282	ClinVar	RCV000783868.10	Nov 01, 2024 (157)
283	ClinVar	RCV000783922.11	Nov 01, 2024 (157)
284	ClinVar	RCV000783923.11	Nov 01, 2024 (157)
285	ClinVar	RCV000783924.10	Nov 01, 2024 (157)
286	ClinVar	RCV000783925.9	Nov 01, 2024 (157)
287	ClinVar	RCV000783926.10	Nov 01, 2024 (157)
288	ClinVar	RCV000783927.10	Nov 01, 2024 (157)
289	ClinVar	RCV000783928.10	Nov 01, 2024 (157)
290	ClinVar	RCV000783929.10	Nov 01, 2024 (157)
291	ClinVar	RCV000783930.10	Nov 01, 2024 (157)
292	ClinVar	RCV000783931.10	Nov 01, 2024 (157)
293	ClinVar	RCV000783932.10	Nov 01, 2024 (157)
294	ClinVar	RCV000784107.10	Nov 01, 2024 (157)
295	ClinVar	RCV000784108.10	Nov 01, 2024 (157)
296	ClinVar	RCV000784109.10	Nov 01, 2024 (157)
297	ClinVar	RCV000784110.10	Nov 01, 2024 (157)
298	ClinVar	RCV000784111.10	Nov 01, 2024 (157)
299	ClinVar	RCV000784112.10	Nov 01, 2024 (157)
300	ClinVar	RCV000784113.10	Nov 01, 2024 (157)
301	ClinVar	RCV000784114.10	Nov 01, 2024 (157)
302	ClinVar	RCV000784115.10	Nov 01, 2024 (157)
303	ClinVar	RCV000784116.10	Nov 01, 2024 (157)
304	ClinVar	RCV000784117.10	Nov 01, 2024 (157)
305	ClinVar	RCV000784118.10	Nov 01, 2024 (157)
306	ClinVar	RCV000784302.10	Nov 01, 2024 (157)
307	ClinVar	RCV000784312.10	Nov 01, 2024 (157)
308	ClinVar	RCV000784313.10	Nov 01, 2024 (157)
309	ClinVar	RCV000784314.10	Nov 01, 2024 (157)
310	ClinVar	RCV000784315.11	Nov 01, 2024 (157)
311	ClinVar	RCV000784316.10	Nov 01, 2024 (157)
312	ClinVar	RCV000784317.10	Nov 01, 2024 (157)
313	ClinVar	RCV000784403.11	Nov 01, 2024 (157)
314	ClinVar	RCV000784404.10	Nov 01, 2024 (157)
315	ClinVar	RCV000784405.10	Nov 01, 2024 (157)
316	ClinVar	RCV000784406.10	Nov 01, 2024 (157)
317	ClinVar	RCV000784407.10	Nov 01, 2024 (157)
318	ClinVar	RCV000784408.9	Nov 01, 2024 (157)
319	ClinVar	RCV000784498.10	Nov 01, 2024 (157)
320	ClinVar	RCV000784499.10	Nov 01, 2024 (157)
321	ClinVar	RCV000784500.10	Nov 01, 2024 (157)
322	ClinVar	RCV000784501.10	Nov 01, 2024 (157)
323	ClinVar	RCV000784502.10	Nov 01, 2024 (157)
324	ClinVar	RCV000784503.10	Nov 01, 2024 (157)
325	ClinVar	RCV000784504.10	Nov 01, 2024 (157)
326	ClinVar	RCV000784505.10	Nov 01, 2024 (157)
327	ClinVar	RCV000784648.10	Nov 01, 2024 (157)
328	ClinVar	RCV000784649.10	Nov 01, 2024 (157)
329	ClinVar	RCV000784650.10	Nov 01, 2024 (157)
330	ClinVar	RCV000784651.10	Nov 01, 2024 (157)
331	ClinVar	RCV000784652.10	Nov 01, 2024 (157)
332	ClinVar	RCV000784653.10	Nov 01, 2024 (157)
333	ClinVar	RCV000784749.10	Nov 01, 2024 (157)
334	ClinVar	RCV000784750.10	Nov 01, 2024 (157)
335	ClinVar	RCV000784751.10	Nov 01, 2024 (157)
336	ClinVar	RCV000784752.11	Nov 01, 2024 (157)
337	ClinVar	RCV000784797.10	Nov 01, 2024 (157)
338	ClinVar	RCV000784798.10	Nov 01, 2024 (157)
339	ClinVar	RCV000784838.11	Nov 01, 2024 (157)
340	ClinVar	RCV000784839.10	Nov 01, 2024 (157)
341	ClinVar	RCV000784840.10	Nov 01, 2024 (157)
342	ClinVar	RCV002280383.1	Nov 01, 2024 (157)

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Associated ID	History Updated (Build)
rs17879456	Mar 11, 2006 (126)
rs60361278	May 25, 2008 (130)
rs116940633	Aug 16, 2010 (132)

Added to this RefSNP Cluster:

Submission IDs	Observation SPDI	Canonical SPDI	Source RSIDs
ss109668150, ss254534604, ss280732378, ss290909232, ss480908553, ss491629939, ss1597477850, ss2710661490	NC_000010.9:96531605:G:A	NC_000010.11:94781858:G:A	(self)
51055232, 28345761, 20116501, 241578, 65940, 2282757, 998632, 12639404, 30133206, 381533, 10870478, 188502, 2115, 13212483, 26844636, 7106686, 28345761, 6294425, ss224884225, ss235292670, ss241975895, ss342304122, ss480927569, ss481884803, ss485249287, ss491001642, ss537221024, ss657184049, ss778532112, ss783070592, ss784028424, ss832328705, ss833988650, ss974475596, ss987804539, ss1067514945, ss1077215449, ss1338623797, ss1575296741, ss1584069479, ss1625196200, ss1668190233, ss1690011937, ss1711265773, ss1751988282, ss1931170553, ss1946289782, ss1959284952, ss1967199824, ss2026313671, ss2154590332, ss2627625777, ss2632748384, ss2698843075, ss2738420845, ss2748441509, ss2892128580, ss3006966091, ss3029638026, ss3349261285, ss3625584961, ss3626509917, ss3630771631, ss3632960313, ss3633657957, ss3634417821, ss3635350236, ss3636102025, ss3637100941, ss3640125162, ss3644542529, ss3646413622, ss3674378253, ss3737585613, ss3744074659, ss3744718792, ss3748468432, ss3772219148, ss3824540950, ss3825780773, ss3832276858, ss3839679578, ss3874827656, ss3922955812, ss3983983378, ss3984449114, ss3984639037, ss3986493465, ss6253826834, ss6307410302, ss6322395607, ss6326442677, ss6332060696, ss6343187327, ss6349787544, ss6403982928, ss6404454508, ss8198969276, ss8237481903, ss8237481905, ss8237481906, ss8237630501, ss8315494519, ss8510129403, ss8512473898, ss8623950097, ss8624011473, ss8624255707, ss8649886005, ss8799403698, ss8799821536, ss8800062047, ss8800161207, ss8824807546, ss8847378110, ss8847605634, ss8848304486, ss8941172579, ss8981728093, ss8981728094, ss8982151829	NC_000010.10:96541615:G:A	NC_000010.11:94781858:G:A	(self)
RCV000018393.33, RCV000018394.37, RCV000018395.35, RCV000352637.13, RCV000610614.9, RCV000782440.10, RCV000782448.11, RCV000782449.10, RCV000782450.9, RCV000782451.10, RCV000782452.10, RCV000782453.10, RCV000782488.10, RCV000782513.10, RCV000782514.11, RCV000782515.11, RCV000782516.10, RCV000782517.10, RCV000782518.10, RCV000782519.10, RCV000782634.10, RCV000782635.10, RCV000782636.10, RCV000782637.10, RCV000782638.10, RCV000782639.10, RCV000782640.10, RCV000782690.10, RCV000782691.10, RCV000782692.10, RCV000782693.10, RCV000782694.10, RCV000782695.10, RCV000782696.10, RCV000782697.9, RCV000782698.10, RCV000782699.10, RCV000782700.10, RCV000782880.10, RCV000782881.10, RCV000782882.10, RCV000782883.10, RCV000782884.10, RCV000782885.10, RCV000782886.10, RCV000782887.10, RCV000783140.10, RCV000783141.10, RCV000783142.10, RCV000783143.10, RCV000783144.10, RCV000783145.10, RCV000783171.10, RCV000783172.10, RCV000783173.10, RCV000783174.10, RCV000783175.10, RCV000783269.10, RCV000783270.10, RCV000783415.10, RCV000783416.10, RCV000783417.10, RCV000783418.10, RCV000783500.10, RCV000783514.10, RCV000783515.10, RCV000783575.10, RCV000783576.10, RCV000783577.10, RCV000783578.10, RCV000783613.10, RCV000783614.10, RCV000783615.10, RCV000783616.9, RCV000783617.10, RCV000783618.10, RCV000783619.10, RCV000783620.10, RCV000783648.10, RCV000783666.11, RCV000783672.10, RCV000783673.10, RCV000783712.10, RCV000783739.10, RCV000783740.10, RCV000783741.10, RCV000783742.10, RCV000783743.10, RCV000783864.10, RCV000783865.10, RCV000783866.10, RCV000783867.10, RCV000783868.10, RCV000783922.11, RCV000783923.11, RCV000783924.10, RCV000783925.9, RCV000783926.10, RCV000783927.10, RCV000783928.10, RCV000783929.10, RCV000783930.10, RCV000783931.10, RCV000783932.10, RCV000784107.10, RCV000784108.10, RCV000784109.10, RCV000784110.10, RCV000784111.10, RCV000784112.10, RCV000784113.10, RCV000784114.10, RCV000784115.10, RCV000784116.10, RCV000784117.10, RCV000784118.10, RCV000784302.10, RCV000784312.10, RCV000784313.10, RCV000784314.10, RCV000784315.11, RCV000784316.10, RCV000784317.10, RCV000784403.11, RCV000784404.10, RCV000784405.10, RCV000784406.10, RCV000784407.10, RCV000784408.9, RCV000784498.10, RCV000784499.10, RCV000784500.10, RCV000784501.10, RCV000784502.10, RCV000784503.10, RCV000784504.10, RCV000784505.10, RCV000784648.10, RCV000784649.10, RCV000784650.10, RCV000784651.10, RCV000784652.10, RCV000784653.10, RCV000784749.10, RCV000784750.10, RCV000784751.10, RCV000784752.11, RCV000784797.10, RCV000784798.10, RCV000784838.11, RCV000784839.10, RCV000784840.10, 67091039, 35745804, 387015388, 468188, 24836466, 32140983, 797194, 1139, 131577935, 78174471, 9569269763, ss1505810974, ss2177148642, ss3026946939, ss3649441579, ss3690461995, ss3771575725, ss3813834603, ss3845153244, ss3968458465, ss4862628816, ss6114202115, ss6322063341, ss6349997714, ss6382289085, ss6404050381, ss6440423965, ss6859879643, ss8236886080, ss8237655806, ss8285088098, ss8314429328, ss8480548060, ss8579565104, ss8745187076, ss8811792439, ss8849697153, ss8880086142, ss8981325922, ss8982040320, ss8982064789	NC_000010.11:94781858:G:A	NC_000010.11:94781858:G:A	(self)
ss20712232	NT_030059.11:15290141:G:A	NC_000010.11:94781858:G:A	(self)
ss6273387, ss24092249, ss28531447, ss32475261, ss38568858, ss65746807, ss66862485, ss69370430, ss71644820, ss76860176, ss79314148, ss84155548, ss97576553, ss137888266, ss159721122, ss160667511, ss244267390	NT_030059.13:47346079:G:A	NC_000010.11:94781858:G:A	(self)
ss8237481904, ss8512473898, ss8624255707	NC_000010.10:96541615:G:C	NC_000010.11:94781858:G:C	(self)
ss38568858	NT_030059.13:47346079:G:C	NC_000010.11:94781858:G:C	(self)
RCV002280383.1, 9569269763	NC_000010.11:94781858:G:T	NC_000010.11:94781858:G:T	(self)

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

284 citations for rs4244285

PMID	Title	Author	Year	Journal
8195181	The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.	de Morais SM et al.	1994	The Journal of biological chemistry
9093256	High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu.	Kaneko A et al.	1997	Lancet (London, England)
11763000	The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.	Yokono A et al.	2001	Journal of clinical psychopharmacology
12012142	The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects.	Jiang ZP et al.	2002	European journal of clinical pharmacology
12172336	The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.	Shimoda K et al.	2002	Journal of clinical psychopharmacology
15168101	Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.	Grasmäder K et al.	2004	European journal of clinical pharmacology
15205367	Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.	Steimer W et al.	2004	Clinical chemistry
15590749	Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.	Steimer W et al.	2005	Clinical chemistry
16024198	CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies.	Koski A et al.	2006	Forensic science international
16044105	Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.	van der Weide J et al.	2005	Therapeutic drug monitoring
16772608	Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.	Hulot JS et al.	2006	Blood
17048007	Association of warfarin dose with genes involved in its action and metabolism.	Wadelius M et al.	2007	Human genetics
17625515	Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.	Rudberg I et al.	2008	Clinical pharmacology and therapeutics
17697139	Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.	Fontana P et al.	2007	Journal of thrombosis and haemostasis
17900275	Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.	Brandt JT et al.	2007	Journal of thrombosis and haemostasis
18004210	Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.	Giusti B et al.	2007	Pharmacogenetics and genomics
18323861	The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.	Kim KA et al.	2008	Clinical pharmacology and therapeutics
18346178	Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.	Chen BL et al.	2008	Clinical and experimental pharmacology & physiology
18394438	Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.	Frere C et al.	2008	The American journal of cardiology
18482659	Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.	Trenk D et al.	2008	Journal of the American College of Cardiology
18521743	CYP2C19*17 is associated with decreased breast cancer risk.	Justenhoven C et al.	2009	Breast cancer research and treatment
18532997	The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.	Umemura K et al.	2008	Journal of thrombosis and haemostasis
18547414	Genotyping panel for assessing response to cancer chemotherapy.	Dai Z et al.	2008	BMC medical genomics
18577829	Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.	Malek LA et al.	2008	Circulation journal
18781853	CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.	Geisler T et al.	2008	Pharmacogenomics
19106083	Genetic determinants of response to clopidogrel and cardiovascular events.	Simon T et al.	2009	The New England journal of medicine
19106084	Cytochrome p-450 polymorphisms and response to clopidogrel.	Mega JL et al.	2009	The New England journal of medicine
19108880	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.	Collet JP et al.	2009	Lancet (London, England)
19136640	Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.	Desta Z et al.	2009	The Journal of pharmacology and experimental therapeutics
19164093	Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.	Matimba A et al.	2009	Human genomics
19193675	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.	Sibbing D et al.	2009	European heart journal
19268736	Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.	Giusti B et al.	2009	The American journal of cardiology
19444287	Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations.	Wang SM et al.	2009	Journal of human genetics
19463375	The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.	Gladding P et al.	2008	JACC. Cardiovascular interventions
19531897	Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.	Jinnai T et al.	2009	Circulation journal
19576320	Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.	Lee JM et al.	2009	The American journal of cardiology
19617466	CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.	Hennessy S et al.	2009	Journal of clinical pharmacology
19624462	CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring.	Aleil B et al.	2009	Journal of thrombosis and haemostasis
19706858	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	Shuldiner AR et al.	2009	JAMA
19841156	Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.	Jin Y et al.	2010	Journal of clinical pharmacology
19890215	CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.	Saitoh A et al.	2010	Journal of acquired immune deficiency syndromes (1999)
19926050	Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.	Gladding P et al.	2009	JACC. Cardiovascular interventions
19934793	Besides CYP2C192, the variant allele CYP2C93 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.	Harmsze A et al.	2010	Pharmacogenetics and genomics
20351750	Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.	Sofi F et al.	2011	The pharmacogenomics journal
20435227	Clinical assessment incorporating a personal genome.	Ashley EA et al.	2010	Lancet (London, England)
20440227	Clopidogrel pathway.	Sangkuhl K et al.	2010	Pharmacogenetics and genomics
20492469	Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.	Sibbing D et al.	2010	Journal of thrombosis and haemostasis
20510210	Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.	Hochholzer W et al.	2010	Journal of the American College of Cardiology
20531370	Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.	de Vos A et al.	2011	The pharmacogenomics journal
20620727	Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.	Hulot JS et al.	2010	Journal of the American College of Cardiology
20650435	Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.	Jeong YH et al.	2010	JACC. Cardiovascular interventions
20708365	Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.	Bonello L et al.	2010	Journal of the American College of Cardiology
20724801	Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous coronary intervention.	Kang MK et al.	2010	Journal of atherosclerosis and thrombosis
20801494	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.	Mega JL et al.	2010	Lancet (London, England)
20801498	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.	Wallentin L et al.	2010	Lancet (London, England)
20833683	CYP2C192 and CYP2C93 alleles are associated with stent thrombosis: a case-control study.	Harmsze AM et al.	2010	European heart journal
20845077	Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.	Jin B et al.	2011	Molecular biology reports
20847277	Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification.	Baak-Pablo R et al.	2010	The Journal of molecular diagnostics
20921971	Mapping genes that predict treatment outcome in admixed populations.	Baye TM et al.	2010	The pharmacogenomics journal
20924183	Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction.	Małek LA et al.	2010	Cardiology
20936101	Pharmacogenetics of Anti-Diabetes Drugs.	Distefano JK et al.	2010	Pharmaceuticals (Basel, Switzerland)
20978260	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.	Mega JL et al.	2010	JAMA
20979470	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.	Paré G et al.	2010	The New England journal of medicine
21071160	Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population.	Shi Y et al.	2011	Forensic science international
21099121	Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.	Sawada T et al.	2011	Circulation journal
21102498	Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.	Onizuka M et al.	2011	Bone marrow transplantation
21163112	Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.	Liu XL et al.	2010	Chinese medical journal
21168310	Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.	Yamamoto K et al.	2011	Journal of cardiology
21178986	Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.	Maeda A et al.	2011	Clinical pharmacology and therapeutics
21192344	CYP2C19 variation and citalopram response.	Mrazek DA et al.	2011	Pharmacogenetics and genomics
21247447	CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.	Santos PC et al.	2011	BMC medical genetics
21289622	Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.	Sadee W et al.	2011	Clinical pharmacology and therapeutics
21358751	Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.	Scott SA et al.	2012	The pharmacogenomics journal
21392617	The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.	Gurbel PA et al.	2011	American heart journal
21426546	The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel.	Pettersen AA et al.	2011	Thrombosis journal
21474982	Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.	Park KJ et al.	2011	The Korean journal of laboratory medicine
21480951	Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.	Lim JS et al.	2011	British journal of clinical pharmacology
21497341	High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19.	Painter JN et al.	2011	Fertility and sterility
21527445	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.	Sibbing D et al.	2011	European heart journal
21546862	PharmGKB summary: citalopram pharmacokinetics pathway.	Sangkuhl K et al.	2011	Pharmacogenetics and genomics
21628721	Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.	Bouman HJ et al.	2011	Heart (British Cardiac Society)
21689142	Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.	Kelly RP et al.	2012	British journal of clinical pharmacology
21700758	Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.	Oh IY et al.	2012	Heart (British Cardiac Society)
21708280	Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis.	Srivastava K et al.	2011	Mutation research
21712189	Analysis of pharmacogenetic traits in two distinct South African populations.	Ikediobi O et al.	2011	Human genomics
21716271	Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.	Scott SA et al.	2011	Clinical pharmacology and therapeutics
21786436	Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.	Lee JB et al.	2011	Yonsei medical journal
21806387	Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.	Rideg O et al.	2011	Pharmacogenomics
21816733	Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.	Bauer T et al.	2011	BMJ (Clinical research ed.)
21831410	CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.	Kassimis G et al.	2012	Thrombosis research
21860339	Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.	Lehr T et al.	2011	Pharmacogenetics and genomics
21881565	Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.	Lewis JP et al.	2011	Clinical pharmacology and therapeutics
21918509	Pharmacogenomics: application to the management of cardiovascular disease.	Johnson JA et al.	2011	Clinical pharmacology and therapeutics
21918510	Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.	Simon T et al.	2011	Clinical pharmacology and therapeutics
21921273	Cardiovascular pharmacogenomics.	Roden DM et al.	2011	Circulation research
21972404	CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.	Hulot JS et al.	2011	Circulation. Cardiovascular interventions
21998633	Functional evaluation of genetic and environmental regulators of p450 mRNA levels.	Wang D et al.	2011	PloS one
22007612	Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.	Kim IS et al.	2012	British journal of clinical pharmacology
22028352	Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.	Cayla G et al.	2011	JAMA
22088980	Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.	Mega JL et al.	2011	JAMA
22190063	Predicting clopidogrel response using DNA samples linked to an electronic health record.	Delaney JT et al.	2012	Clinical pharmacology and therapeutics
22228204	The influence of CYP2C192 and 17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting.	Harmsze AM et al.	2012	Pharmacogenetics and genomics
22265638	The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.	Namazi S et al.	2012	Biochemical pharmacology
22285300	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.	Bonello L et al.	2012	Thrombosis research
22427735	Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.	Kreutz RP et al.	2012	Clinical pharmacology
22462746	CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.	Chan MY et al.	2012	Pharmacogenomics
22479249	Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.	Philips S et al.	2012	Frontiers in pharmacology
22491019	Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.	Martis S et al.	2013	The pharmacogenomics journal
22569204	PharmGKB summary: phenytoin pathway.	Thorn CF et al.	2012	Pharmacogenetics and genomics
22624833	Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.	Price MJ et al.	2012	Journal of the American College of Cardiology
22702493	Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.	Seredina TA et al.	2012	BMC medical genetics
22723959	Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population.	Chen DY et al.	2012	PloS one
22784880	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.	Wiese MD et al.	2012	Arthritis research & therapy
22940005	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.	Verschuren JJ et al.	2013	International journal of cardiology
22990067	Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.	Wu H et al.	2012	Pharmacogenetics and genomics
22992668	Pharmacogenomics knowledge for personalized medicine.	Whirl-Carrillo M et al.	2012	Clinical pharmacology and therapeutics
23089684	Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.	Pimenoff VN et al.	2012	Pharmacogenetics and genomics
23104099	Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.	Bertrand J et al.	2012	Pharmacogenetics and genomics
23111422	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.	Lubomirov R et al.	2013	Pharmacogenetics and genomics
23133420	Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.	Suarez-Kurtz G et al.	2012	Frontiers in pharmacology
23175667	Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.	Bosó V et al.	2013	Drug metabolism and disposition
23300409	Chapter 7: Pharmacogenomics.	Karczewski KJ et al.	2012	PLoS computational biology
23364775	Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.	Carlquist JF et al.	2013	Thrombosis and haemostasis
23645039	High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature.	Sipeky C et al.	2013	Molecular biology reports
23661171	CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.	Mejin M et al.	2013	International journal of clinical pharmacy
23687222	Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.	Vardhanabhuti S et al.	2013	The Journal of infectious diseases
23697979	Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?	Perry CG et al.	2013	Journal of human genetics
23698643	Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.	Scott SA et al.	2013	Clinical pharmacology and therapeutics
23766564	Pharmacogenetics of chronic pain and its treatment.	Světlík S et al.	2013	Mediators of inflammation
23797323	Pharmacogenomics of anti-platelet and anti-coagulation therapy.	Fisch AS et al.	2013	Current cardiology reports
23810503	Comparison of high-resolution melting analysis, TaqMan Allelic discrimination assay, and sanger sequencing for Clopidogrel efficacy genotyping in routine molecular diagnostics.	Zhang L et al.	2013	The Journal of molecular diagnostics
23895809	Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention.	Pendyala LK et al.	2013	American heart journal
24016178	Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.	Wang SC et al.	2013	Omics
24353446	Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response.	Kreutz RP et al.	2013	Clinical pharmacology
24357089	Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.	Wang TH et al.	2014	The AAPS journal
24519754	CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.	Burns KE et al.	2014	Cancer chemotherapy and pharmacology
24710841	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.	Horenstein RB et al.	2014	Journal of clinical pharmacology
24762860	Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.	Cresci S et al.	2014	Circulation. Cardiovascular genetics
24796765	Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis.	Painter JN et al.	2014	Fertility and sterility
24944790	Screening for 392 polymorphisms in 141 pharmacogenes.	Kim JY et al.	2014	Biomedical reports
25051347	Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.	Siller-Matula JM et al.	2014	PloS one
25126975	A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.	Chen J et al.	2014	PloS one
25266489	Genetic polymorphisms of VIP variants in the Tajik ethnic group of northwest China.	Zhang J et al.	2014	BMC genetics
25419701	Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations.	Bonifaz-Peña V et al.	2014	PloS one
25714468	A systematic approach to the reporting of medically relevant findings from whole genome sequencing.	McLaughlin HM et al.	2014	BMC medical genetics
25730082	Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.	Sun B et al.	2015	Genetics and molecular research
25860557	Correlation Between SNPs in Candidate Genes and VerifyNow-Detected Platelet Responsiveness to Aspirin and Clopidogrel Treatment.	Cui H et al.	2015	Cardiovascular drugs and therapy
25897256	Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.	Beitelshees AL et al.	2015	Pharmacogenomics and personalized medicine
26021325	The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C1935 and CYP2C192 Alleles.	Chaudhry AS et al.	2015	Drug metabolism and disposition
26091847	Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.	Wang L et al.	2015	BMC genetics
26263974	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.	Simeon V et al.	2015	International journal of molecular sciences
26323597	Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.	Shirasaka Y et al.	2016	The pharmacogenomics journal
26444257	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics.	Chan SL et al.	2016	Pharmacogenetics and genomics
26757134	Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.	Khalil BM et al.	2016	Clinical and translational science
26773420	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.	Veal GJ et al.	2016	European journal of cancer (Oxford, England
26781306	Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy.	Jin T et al.	2016	Molecular medicine reports
26785747	Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan.	Iskakova AN et al.	2016	BMC genetics
26801900	Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.	Cocca M et al.	2016	Journal of translational medicine
26858644	Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX(®) ADME PGx Panel for Pharmacogenomic Profiling.	Chua EW et al.	2016	Frontiers in pharmacology
26870959	Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting.	Li XQ et al.	2016	PloS one
26961113	Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.	Yi X et al.	2016	Journal of atherosclerosis and thrombosis
27002825	Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.	Audemard-Verger A et al.	2016	PloS one
27010727	Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.	Yang HC et al.	2016	PLoS genetics
27110117	Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.	Medhasi S et al.	2016	Neuropsychiatric disease and treatment
27133299	Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.	Liu R et al.	2016	Acta pharmacologica Sinica
27171561	Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings.	Voican CS et al.	2016	PloS one
27233747	Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.	Yi X et al.	2017	Clinical and applied thrombosis/hemostasis
27233804	Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.	Jin T et al.	2016	BMC genetics
27249515	Evidence for extensive pleiotropy among pharmacogenes.	Oetjens MT et al.	2016	Pharmacogenomics
27296832	ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.	Fukunaga K et al.	2016	BMC genetics
27368038	CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.	Choi IJ et al.	2016	Medicine
27529241	The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?	Daud AN et al.	2016	International journal of molecular sciences
27728892	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.	Tang XF et al.	2016	Thrombosis research
27915083	Pharmacodynamic and cytogenetic evaluation in CYP2C192 and CYP2C193 allelomorphism in South Indian population with clopidogrel therapy.	Tantray JA et al.	2017	International journal of cardiology
27981573	Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel.	Zhong WP et al.	2017	Clinical pharmacology and therapeutics
28066799	The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent.	Dávila-Fajardo CL et al.	2017	Data in brief
28095090	Associations between Rs4244285 and Rs762551 gene polymorphisms and age-related macular degeneration.	Stasiukonyte N et al.	2017	Ophthalmic genetics
28178648	Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.	Kuo SH et al.	2017	Oncotarget
28280103	Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.	Li XG et al.	2017	Postgraduate medical journal
28321040	Whole exome sequencing detects variants of genes that mediate response to anticancer drugs.	Ohnami S et al.	2017	The Journal of toxicological sciences
28343093	Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.	López-García MA et al.	2017	Pharmacological reports
28378544	Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.	Park S et al.	2017	Journal of Korean medical science
28513222	The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.	Polonikov A et al.	2017	Clinical and experimental hypertension (New York, N.Y.
28604225	The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy.	Tatarunas V et al.	2017	Pharmacogenomics
28652652	Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.	Sharma A et al.	2017	World journal of gastroenterology
28687336	Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.	Polonikov A et al.	2017	Gene
28785581	CYP2C19(⁎)2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls.	Ruedlinger J et al.	2017	BioMed research international
28806186	The impact of CYP2C192, CYP4F23, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy.	Tatarunas V et al.	2017	Blood coagulation & fibrinolysis
29033601	Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients.	Denisenko NP et al.	2017	Pharmacogenomics and personalized medicine
29167499	A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance.	Zhang L et al.	2017	Scientific reports
29193749	Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years.	Borobia AM et al.	2018	Clinical and translational science
29260275	Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.	Novkovic M et al.	2018	European journal of clinical pharmacology
29407631	Genetic mutations in PEAR1 associated with cardiovascular outcomes in Chinese patients with acute coronary syndrome.	Nie XY et al.	2018	Thrombosis research
29449662	Assessment of interaction between maternal polycyclic aromatic hydrocarbons exposure and genetic polymorphisms on the risk of congenital heart diseases.	Li N et al.	2018	Scientific reports
29461866	The Prognostic Value of Combinations of Genetic Polymorphisms in the ITGB3, ITGA2, and CYP2C19*2 Genes in Predicting Cardiovascular Outcomes After Coronary Bypass Grafting.	Grinshtein YI et al.	2018	Genetic testing and molecular biomarkers
29478129	Gene polymorphisms in dual antiplatelet therapy and the presence of hypo-attenuated leaflet thickening after transcatheter aortic valve replacement.	Xiong TY et al.	2018	Journal of thrombosis and thrombolysis
29482947	Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women.	Jabir FA et al.	2018	Clinical breast cancer
29517409	Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.	Xiao W et al.	2018	Pharmacogenomics
29623639	Pharmacogenetics of Opioid Use Disorder Treatment.	Crist RC et al.	2018	CNS drugs
29666902	Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.	Mei S et al.	2018	European journal of clinical pharmacology
29681089	Genetic variation in biotransformation enzymes, air pollution exposures, and risk of spina bifida.	Padula AM et al.	2018	American journal of medical genetics. Part A
29756345	Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.	Kharasch ED et al.	2019	Clinical pharmacology and therapeutics
29804161	Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.	Lin J et al.	2018	European journal of clinical pharmacology
29950882	CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.	Denisenko NP et al.	2018	Pharmacogenomics and personalized medicine
30068618	Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.	Collin LJ et al.	2018	BMJ open
30081812	[Possible Genetic Predictors of Cardiovascular Complications After Coronary Artery Bypass Surgery].	Grinshtein YI et al.	2018	Kardiologiia
30093869	Biological Predictors of Clozapine Response: A Systematic Review.	Samanaite R et al.	2018	Frontiers in psychiatry
30096456	CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.	Wang JY et al.	2018	Gene
30128710	Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.	Yi X et al.	2018	Journal of neurology
30135031	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.	Fabbri C et al.	2018	European neuropsychopharmacology
30606386	[Correlation between CYP2C19 Gene Polymorphism and Elderly Cerebral Infarction].	Fan DJ et al.	2018	Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
30706164	Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers.	Ariffin NM et al.	2019	Parasitology research
30742211	Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.	Pan Y et al.	2019	JAMA neurology
30758238	Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.	Langaee T et al.	2019	Genetic testing and molecular biomarkers
30826566	CYP2C19*2 polymorphism in Polish peptic ulcer patients.	Sałagacka-Kubiak A et al.	2019	Pharmacological reports
31019283	Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests.	Thauvin-Robinet C et al.	2019	European journal of human genetics
31086207	Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.	Afsar NA et al.	2019	Scientific reports
31184624	[Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].	Sychev DA et al.	2019	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
31270413
31543510	Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.	Su Q et al.	2019	Medical science monitor
31807051	Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects.	Dorofeeva MN et al.	2019	Pharmacogenomics and personalized medicine
31821471	Polymorphisms and endometriosis: a systematic review and meta-analyses.	Méar L et al.	2020	Human reproduction update
31870130	Association of CYP1A1 rs1048943 Polymorphism with Prostate Cancer in Iraqi Men Patients.	Hoidy WH et al.	2019	Asian Pacific journal of cancer prevention
31957548	Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder.	Zastrozhin MS et al.	2020	Pharmacogenomics
31998606	New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases.	Lu J et al.	2020	Acta pharmaceutica Sinica. B
32001263	Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases.	Sharma AR et al.	2020	Life sciences
32134726	How do CYP2C192 and CYP2C1917 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?	Skryabin VY et al.	2020	Drug metabolism and personalized therapy
32158254	CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.	Sychev DA et al.	2020	Pharmacogenomics and personalized medicine
32228310	Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients.	Rojo M et al.	2020	Clinical and applied thrombosis/hemostasis
32303955	Clinically relevant pharmacogenetic markers in Tatars and Balkars.	Abdullaev SP et al.	2020	Molecular biology reports
32326111	Role of Genetic Variations in the Hepatic Handling of Drugs.	Marin JJG et al.	2020	International journal of molecular sciences
32345264	Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel.	Yi X et al.	2020	BMC neurology
32392440	The Frequency of the Minor Polymorphisms in the CYP2C19, VEGFR-2 Genes, and Clinical Outcomes in Russian and Buryat Patients with Acute Coronary Syndrome.	Zelenskaya EM et al.	2020	Genetic testing and molecular biomarkers
32472697	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.	Verma SS et al.	2020	Clinical pharmacology and therapeutics
32567426	An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children.	Makowska M et al.	2021	The International journal of neuroscience
32607875	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.	Yin A et al.	2021	Clinical pharmacokinetics
32639515	Bayesian Pathway Analysis for Complex Interactions.	Baurley JW et al.	2020	American journal of epidemiology
32862511	Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.	Ma L et al.	2020	International journal of immunogenetics
32872162	Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450.	Hlaváč V et al.	2020	Journal of personalized medicine
33093222	F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA.	Pan Y et al.	2021	Neurology
33124772	Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.	Chuwongwattana S et al.	2020	Pharmacology research & perspectives
33192522	Pleiotropic Functions of Cytochrome P450 Monooxygenase-Derived Eicosanoids in Cancer.	Luo Y et al.	2020	Frontiers in pharmacology
33217013	Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.	Yip VLM et al.	2021	British journal of clinical pharmacology
33423267	[Association of CYP2C19 and CYP3A5 gene polymorphisms with myocardial infarction].	Qi L et al.	2021	Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
33430289	Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans.	Han N et al.	2021	Journal of personalized medicine
33519226	Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.	Fernandes MR et al.	2021	Pharmacogenomics and personalized medicine
33569925	Gene-environment interactions between air pollution and biotransformation enzymes and risk of birth defects.	Padula AM et al.	2021	Birth defects research
33580125	Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients.	Duflot T et al.	2021	Scientific reports
33804537	Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.	Iannaccone T et al.	2021	Pharmaceuticals (Basel, Switzerland)
33805706	SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability.	Zubiaur P et al.	2021	Journal of personalized medicine
33875422	Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment.	Pernaute-Lau L et al.	2021	Antimicrobial agents and chemotherapy
33995083	Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism.	Mejía-Abril G et al.	2021	Frontiers in pharmacology
34062203	Variation in biomarker levels of metals, persistent organic pollutants, and omega-3 fatty acids in association with genetic polymorphisms among Inuit in Nunavik, Canada.	Parajuli RP et al.	2021	Environmental research
34163711	Universal and high-fidelity DNA single nucleotide polymorphism detection based on a CRISPR/Cas12a biochip.	Chen Y et al.	2021	Chemical science
34382722	Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.	Ndadza A et al.	2021	Journal of thrombosis and haemostasis
34385834	Individualized Drugs' Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process.	Borro M et al.	2021	Pharmacogenomics and personalized medicine
34415683	Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach.	Duconge J et al.	2021	Clinical and translational science
34429635	Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population.	He C et al.	2021	Pharmacogenomics and personalized medicine
34434063	Genetic Polymorphisms of Pesticide-Metabolizing Enzymes and Transporters in Agricultural Workers and Thyroid Hormone Levels.	Sirivarasai J et al.	2021	Risk management and healthcare policy
34621706	Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.	Kim B et al.	2021	Translational and clinical pharmacology
34690761	Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin.	Villapalos-García G et al.	2021	Frontiers in pharmacology
34747629	Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.	Makarem YS et al.	2021	Pharmacogenomics
34798807	Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China.	Li D et al.	2021	BMC genomic data
34848811	Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.	Wang S et al.	2021	Scientific reports
34920277	Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphisms.	Stajnko A et al.	2022	Environment international
34949935	Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China.	Wang Y et al.	2021	Pharmacogenomics and personalized medicine
34958284	Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.	Muyambo S et al.	2022	Omics
35089958	Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.	Goljan E et al.	2022	PloS one
35235711	Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.	Zhou S et al.	2022	Clinical and translational science
35572141	Polymorphisms of Cytochromes P450 and Glutathione S-Transferases Synergistically Modulate Risk for Parkinson's Disease.	Fan HH et al.	2022	Frontiers in aging neuroscience
35574727	Population features of alleles and genotypes frequency distribution of polymorphic genetic markers of antipsychotic medications pharmacokinetics in the Kazakh population.	Saduakassova KZ et al.	2022	American journal of medical genetics. Part B, Neuropsychiatric genetics
35646073	SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population.	Xie Q et al.	2022	Frontiers in genetics
35761855	Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.	Nthontho KC et al.	2022	Pharmacogenomics and personalized medicine
35846994	Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.	Silgado-Guzmán DF et al.	2022	Frontiers in pharmacology
35929455	Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention.	Zong J et al.	2022	Journal of the American Heart Association
36065758	CYP2C83 and 4 define CYP2C8 phenotype: An approach with the substrate cinitapride.	Campodónico DM et al.	2022	Clinical and translational science
36164570	Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.	Alshabeeb MA et al.	2022	Saudi pharmaceutical journal
36211438	Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.	Muñiz P et al.	2022	Frontiers in immunology
36222113	Impact of CYP2C19 gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis.	Wang D et al.	2022	Pharmacogenomics
36245136	Nutritional and genetic determinants of essential hypertension among adult respondents of the 2013 national nutrition survey, Philippines: a preliminary observational study.	Zumaraga MPP et al.	2022	The Journal of nutritional biochemistry
36333412	Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.	Joas E et al.	2023	The pharmacogenomics journal
36404298	Genome-wide analyses identify novel risk loci for cluster headache in Han Chinese residing in Taiwan.	Chen SP et al.	2022	The journal of headache and pain
36453946	Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study.	Xiang Q et al.	2022	Clinical and translational medicine
36825998	SNPs Sets in Codifying Genes for Xenobiotics-Processing Enzymes Are Associated with COPD Secondary to Biomass-Burning Smoke.	Ambrocio-Ortiz E et al.	2023	Current issues in molecular biology

The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.

Genome context:

Select flank length:

Genomic regions, transcripts, and products
Top▲ Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Choose placement

dbSNP Short Genetic Variations

Welcome to the Reference SNP (rs) Report

Reference SNP (rs) Report

rs4244285